CN109239332A - A kind of kit of auxiliary detection sub-health population cancer base antigen - Google Patents

A kind of kit of auxiliary detection sub-health population cancer base antigen Download PDF

Info

Publication number
CN109239332A
CN109239332A CN201811066799.9A CN201811066799A CN109239332A CN 109239332 A CN109239332 A CN 109239332A CN 201811066799 A CN201811066799 A CN 201811066799A CN 109239332 A CN109239332 A CN 109239332A
Authority
CN
China
Prior art keywords
bsa
serum albumin
bovine serum
concentration
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201811066799.9A
Other languages
Chinese (zh)
Inventor
赵彦涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Laike Baiao Biotechnology Co Ltd
Original Assignee
Beijing Laike Baiao Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Laike Baiao Biotechnology Co Ltd filed Critical Beijing Laike Baiao Biotechnology Co Ltd
Priority to CN201811066799.9A priority Critical patent/CN109239332A/en
Publication of CN109239332A publication Critical patent/CN109239332A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/537—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody
    • G01N33/538—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with separation of immune complex from unbound antigen or antibody by sorbent column, particles or resin strip, i.e. sorbent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54326—Magnetic particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Abstract

The invention discloses the kits that a kind of auxiliary for belonging to technical field of biological detects sub-health population cancer base antigen.The kit includes carcinomebryonic antigen calibration object, cancer base antigen quality-control product, the Tris buffer of Cea Monoclonal Antibodies and bovine serum albumin(BSA) containing biotin labeling 1, the buffer of Cea Monoclonal Antibodies and bovine serum albumin(BSA) containing alkali phosphatase enzyme mark 2, the Tris buffer of magnetic particle and bovine serum albumin(BSA) containing marked by streptavidin 3, chemical substrate and cleaning solution.The kit high sensitivity, easy to operate, no radiocontamination, low in cost, reaction process is fast and reliable, improves sensitivity and linear measurement range, it realizes quantitative determination, provides a suitable theoretical judgment for the state of an illness of sub-health population common disease and broad-spectrum tumor screening.

Description

A kind of kit of auxiliary detection sub-health population cancer base antigen
Technical field
The invention belongs to technical field of biological, and in particular to a kind of to assist detecting sub-health population cancer base antigen Kit.
Background technique
Inferior health refers to a kind of state that human body is between health and disease.In sub-health state person, cannot reach The standard of health shows as the symptom that the vigor in certain time reduces, function and adaptability decline, does not meet modern doctor The clinic or subclinical inflammation standard for there are related disorders are learned, but the proposition of inferior health idea has highly important medical value And clinical meaning, because it can promote the critical period of the prevention and treatment of disease to move forward.In recent years, due to environmental pollution, swash Strong competition, people's lives and work rhythm are constantly accelerated, and the pressure from society and various aspects is continuously increased, along with suction Cigarette excessive drinking, high heat high fat diet lack the bad habits such as manual labor, life is irregular, night life is excessive, inferior health The ratio that state crowd accounts for population of China gradually increases.Inferior health has severely impacted people's lives, study and work Make, becomes pervasive social problem, become the restraining factors of social development, harmfulness is considered century people by medical field Class health formidable enemy.
Cancer base antigen (carcinoembryonic antigen, CEA) is a kind of with the decision of human embryos antigen-specific The sugar antigen of cluster is present in the cancer cell surface that endoderm cell differentiates, and is the structural proteins of cell membrane.Cancer embryo Antigen is important tumor associated antigen, it belongs to non-organ specificity tumor associated antigen, is primarily present in Rectum and colon cancer In tissue and fetus intestinal mucosa, the Specific marker of early diagnosis colon cancer and the carcinoma of the rectum can be used as, through a large amount of clinical Practice finds that the malignant tumour CEA value of not only gastrointestinal tract can increase, in the serum of breast cancer, lung cancer and other malignant tumours In also have raising.CEA raising is common in colorectal cancer, cancer of pancreas, gastric cancer, breast cancer, medullary carcinoma of thyroid gland, liver cancer, lung cancer, ovum Nest cancer, urological cancer etc., and smoke, the gestational period and cardiovascular disease, diabetes, enteron aisle diverticulitis, rectal polyp, colon Inflammation, pancreatitis, cirrhosis, hepatitis, pulmonary disease etc., 15%~53% patients serum CEA can also be increased.The ginseng of general CEA It examines range and is less than 5ng/Ml, when the constant height of CEA concentration or numerical value are more than normal 56 times, then explanation has lesion Remaining or progress, also or prognosis mala, it is believed that have metastatic lesion.Therefore, it is swollen to be not only a kind of wide spectrum for carcinomebryonic antigen Tumor markers also provide a suitable theoretical judgment to the state of an illness of some common diseases, be malignant tumour antidiastole, State of illness monitoring, therapeutic evaluation etc., provide important clinical value.
The universal law of the life and health development of people is: life and health period --- sub-health state initial stage --- is sub- strong The Kang Fazhan reversible refunding, --- the disease controllable phase --- disease develops the deterioration phase --- was dead.When people are in inferior health development When the reversible refunding, the institutional framework of the cell of the internal body of people and various internal organs, all different degrees of gradually changes , if be chronically under sub-health state, a possibility that canceration occurs for cell, is greatly increased, and the detection of cancer base antigen is Our screenings for the tumour of sub-health population, assist it to judge inferior health degree, have great importance, therefore we It needs to be timed the cancer base antigen of the sub-health state of people or periodically carry out testing and evaluation.Nowadays, carcinomebryonic antigen is normal The detection method seen includes radio immunoassay and indirect immunofluorescence, and radioimmunoassay fluorescence method is due to higher cost And need tip complex device to prevent radiocontamination, indirect immunofluorescence it is complicated for operation and can only carry out qualitative analysis and Sensitivity is low, and quantitative analysis cannot be carried out for the carcinomebryonic antigen of sub-health population, it is therefore desirable to and it is a kind of easy to operate, at This cheap, high sensitivity, no radiocontamination and the method for being able to carry out quantitative analysis.
Summary of the invention
For overcome the deficiencies in the prior art, the present invention provides a kind of high sensitivities, easy to operate, no radiocontamination, Low-cost kit, invention are achieved through the following technical solutions.
The purpose of the present invention is to provide the kits and preparation method of auxiliary detection sub-health population cancer base antigen.
A kind of kit of auxiliary detection sub-health population cancer base antigen, the kit include:
1) carcinomebryonic antigen calibration object, the phosphate buffered saline solution containing carcinomebryonic antigen and bovine serum albumin(BSA), the cow's serum The phosphate buffered saline solution of albumin includes following component, bovine serum albumin(BSA) 30-34g, potassium dihydrogen phosphate powder 0.2- 0.4g, disodium hydrogen phosphate powder 1-2g, sodium chloride powder 7-9g, potassium chloride powder 0.2-0.4g, the salt of concentration 36%~38% Sour 0.1-1mL, the Proclin300 solution 0.1-0.2mL of concentration 98%, deionized water 700-900mL, the carcinomebryonic antigen Calibration object is 6 horizontal liquid calibration objects, in 6 horizontal calibration objects the concentration containing carcinomebryonic antigen be respectively 0,5, 25,100,500 and 1000ng/mL, pH 7.2-7.4；
2) cancer base antigen quality-control product, the phosphate buffered saline solution containing one containing carcinomebryonic antigen and bovine serum albumin(BSA), the ox Sero-abluminous phosphate buffered saline solution is that the phosphate-buffered salt of the bovine serum albumin(BSA) of the carcinomebryonic antigen calibration object is molten Liquid, the carcinomebryonic antigen quality-control product include 2 horizontal liquid calibration objects, carcinomebryonic antigen in 2 horizontal liquid quality controls Target value concentration be 10ng/mL and 100ng/mL, pH 7.2-7.4；
3) reagent 1, the Tris buffer of Cea Monoclonal Antibodies and bovine serum albumin(BSA) containing biotin labeling No. 1, Tris buffer 1 of the bovine serum albumin(BSA) includes following component, bovine serum albumin(BSA) 3-5g, tromethamine Powder 6-10g, sodium chloride powder 3-5g, the hydrochloric acid 0.1-1mL of concentration 36%~38%, the Proclin300 of concentration 98% are molten Liquid 0.1-0.2mL, deionized water 700-900mL；
4) reagent 2, the buffering of Cea Monoclonal Antibodies and bovine serum albumin(BSA) containing alkali phosphatase enzyme mark Liquid 2, buffer 2 of the bovine serum albumin(BSA) include following component, 4- hydroxyethyl piperazineethanesulfonic acid powder 4-6g, chlorine Change sodium powder end 5-8g, bovine serum albumin(BSA) 3-5g, zinc chloride powder 0.05-0.1g, magnesium chloride powder 0.05-0.1g, concentration 36%~38% hydrochloric acid 0.1-1mL, Proclin300 the solution 0.1-0.2mL, deionized water 700- of concentration 98% 900mL；
5) Magneto separate reagent, the Tris buffer 3 of magnetic particle and bovine serum albumin(BSA) containing marked by streptavidin Number, Tris buffer 3 of the bovine serum albumin(BSA) include following component, bovine serum albumin(BSA) 3-5g, cow's serum 30- 50g, tromethamine powder 6-10g, sodium chloride powder 5-8g, the hydrochloric acid 0.1-1mL of concentration 36%~38%, concentration 98% Proclin300 solution 0.1-0.2mL, deionized water 700-900mL；
6) chemical substrate, the chemical substrate include following component, tromethamine powder 15-25g, ethylenediamine tetrem Acid disodium powder 15-25g, sodium chloride powder 15-20g, dioxane compound 0.2-0.6g, lauryl sodium sulfate 0.05-0.1g, glycerine 35-45g, sodium sulfite 0.05-0.1g, the Proclin300 solution 0.1-0.2mL of concentration 98%, Deionized water 700-900mL；
7) cleaning solution, the cleaning solution include following component, tromethamine powder 6-10g, sodium chloride powder 5-8g, Polyoxyethylene 20 sorbitan monolaurate powder 3-5g, Triton X-100 3-5g, concentration 36%~38% Hydrochloric acid 0.1-1mL, deionized water 700-900mL, the pH value of the cleaning solution are 7.5-8.0.
Preferably, in the kit of the auxiliary detection sub-health population cancer base antigen, the carcinomebryonic antigen calibration Product, the carcinomebryonic antigen quality-control product, the reagent 1, the reagent 2, the Magneto separate reagent, the chemical substrate Storage temperature is 2-8 DEG C, and the storage temperature of the cleaning solution is 10-30 DEG C of room temperature, and the kit avoids direct sunlight.
Preferably, biological in the reagent 1 in the kit of the auxiliary detection sub-health population cancer base antigen The concentration of the Cea Monoclonal Antibodies of element label is 0.1-0.3 μ g/mL, pH value 7.0-7.5, alkali in the reagent 2 The concentration of the Cea Monoclonal Antibodies of acid phosphatase label is 0.02-0.1 μ g/mL, pH value 7.5-8.0, the magnetic point Concentration from reagent is 0.5ng/mL, and pH value 7.9-8.1, the diameter of the magnetic particle is 0.5-3.5 μm, kernel four Fe 3 O, surface are wrapped in the polymer containing carboxyl, and the concentration of dioxane compound is in the chemical substrate 0.5mg/mL, pH value 9.2-9.5.
Preferably, in the kit of the auxiliary detection sub-health population cancer base antigen, the bovine serum albumin(BSA) Tris buffer 1, in Tris buffer 3 of the buffer of the bovine serum albumin(BSA) 2 and the bovine serum albumin(BSA) Casein 3-5g can also be added.
Preferably, in the kit of the auxiliary detection sub-health population cancer base antigen, the bovine serum albumin(BSA) Tris buffer 1, in Tris buffer 3 of the buffer of the bovine serum albumin(BSA) 2 and the bovine serum albumin(BSA) N- hydroxysuccinimide powder 3-5g can also be added.
Preferably, in the kit of the auxiliary detection sub-health population cancer base antigen, the bovine serum albumin(BSA) Tris buffer 1, in Tris buffer 3 of the buffer of the bovine serum albumin(BSA) 2 and the bovine serum albumin(BSA) (Na can also be added2.3K0.7)(B6O10)(N O3) powder 3-5g.
The preparation method of the kit of above-mentioned auxiliary detection sub-health population cancer base antigen, carries out in accordance with the following steps:
(1) carcinomebryonic antigen calibration object is prepared: by potassium dihydrogen phosphate powder 0.2-0.4g, disodium hydrogen phosphate powder 1-2g, chlorine Change sodium powder end 7-9g, potassium chloride powder 0.2-0.4g, the Proclin300 solution 0.1-0.2mL of concentration 98%, deionized water 700-900mL is added to the container, and is stirred well to and is completely dissolved, and the hydrochloric acid 0.1-1mL of concentration 36%~38% is added, by pH Value is adjusted to 7.2-7.4, and bovine serum albumin(BSA) 30-34g is added to the container, is stirred well to and is completely dissolved, with 0.3 μm of aperture Filter filtering after bovine serum albumin(BSA) phosphate buffered saline solution, the phosphoric acid of cancer base antigen bovine serum albumin(BSA) is delayed Rushing salting liquid and being diluted to each concentration point is 0,5,25,100,500 and 1000ng/mL；
(2) cancer base antigen quality-control product is prepared: cancer base antigen is dilute with the phosphate buffered saline solution of above-mentioned bovine serum albumin(BSA) Releasing to each concentration point is 10ng/mL and 100ng/mL；
(3) reagent preparation 1: by tromethamine powder 6-10g, sodium chloride powder 3-5g, concentration 98% Proclin300 solution 0.1-0.2mL, deionized water 700-900mL are added to the container, are stirred well to and are completely dissolved, and are added The hydrochloric acid 0.1-1mL of concentration 36%~38%, is adjusted to 7.0-7.5 for pH value, and bovine serum albumin(BSA) 3-5g is added to the container, It is stirred well to and is completely dissolved, Tris buffer 1 of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture, it is conventional Method prepares Cea Monoclonal Antibodies --- the solution of biotin conjugate, with the Tris buffer 1 of bovine serum albumin(BSA) Number containing Cea Monoclonal Antibodies --- the solution of biotin conjugate is diluted to 0.1-0.3 μ g/mL, obtains reagent 1 Number；
(4) reagent preparation 2: by 4- hydroxyethyl piperazineethanesulfonic acid powder 4-6g, sodium chloride powder 5-8g, chlorination zinc powder Last 0.05-0.1g, magnesium chloride powder 0.05-0.1g, the Proclin300 solution 0.1-0.2mL of concentration 98%, deionized water 700-900mL is added to the container, and is stirred well to and is completely dissolved, and the hydrochloric acid 0.1-1mL of concentration 36%~38% is added, by pH Value is adjusted to 7.5-8.0, and bovine serum albumin(BSA) 3-5g is added to the container, is stirred well to and is completely dissolved, with 0.3 μm of aperture Buffer 2 of bovine serum albumin(BSA) are obtained after filter filtering, conventional method prepares Cea Monoclonal Antibodies --- alkaline phosphorus The solution of sour enzyme attachment will contain Cea Monoclonal Antibodies with buffer 2 of bovine serum albumin(BSA) --- alkaline phosphorus The solution of sour enzyme attachment is diluted to 0.02-0.1 μ g/mL, obtains reagent 2；
(5) Magneto separate reagent is prepared: by tromethamine powder 6-10g, sodium chloride powder 5-8g, deionized water 700- 900mL is added to the container, and is stirred well to and is completely dissolved, by bovine serum albumin(BSA) 3-5g, cow's serum 30-50g, concentration 98% Proclin300 solution 0.1-0.2mL be added to the container, be stirred well to and be completely dissolved, concentration 36%~38% is added PH value is adjusted to 7.9-8.1 by hydrochloric acid 0.1-1mL, and the Tris that bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture is slow Fliud flushing 3, conventional method prepares magnetic particle --- the solution of Streptavidin attachment, with the Tris of bovine serum albumin(BSA) Buffer 3 will contain magnetic particle --- and the solution of Streptavidin attachment is diluted to 0.5ng/mL, obtains Magneto separate examination Agent；
(6) chemical substrate is prepared: by tromethamine powder 15-25g, disodium ethylene diamine tetraacetate powder 15-25g, chlorine Change sodium powder end 15-20g, lauryl sodium sulfate 0.05-0.1g, glycerine 35-45g, sodium sulfite 0.05-0.1g, concentration 98% Proclin300 solution 0.1-0.2mL, deionized water 700-900mL are added to the container, and are stirred well to completely molten Solution is added the hydrochloric acid 0.1-1mL of concentration 36%~38%, the pH value of solution is adjusted to 9.2-9.5, with 0.3 μm of the filter in aperture Dioxane compound 0.2-0.6g is added after filtering under light protected environment, being configured to concentration is 0.5mg/mL, obtains chemical bottom Object；
(7) cleaning solution is prepared: by tromethamine powder 6-10g, sodium chloride powder 5-8g, polyoxyethylene sorbitan Alcohol monolaurate powder 3-5g, Triton X-100 3-5g, deionized water 700-900mL are added to the container, sufficiently Stirring is added the hydrochloric acid 0.1-1mL of concentration 36%~38%, the pH value of solution is adjusted to 7.5-8.0, uses hole to being completely dissolved Cleaning solution is obtained after the filter filtering that 0.3 μm of diameter.
Casein 3-5g can be also added in the step (5) in the step (3), the step (4).
N- hydroxysuccinimide powder 3- can be also added in the step (5) in the step (3), the step (4) 5g。
(Na can be also added in the step (5) in the step (3), the step (4)2.3K0.7)(B6 O10)(N O3) powder Last 3-5g.
Testing principle of the invention: by sample to be tested, No. 1 mixing of reagent is incubated, the biotin labeling in reagent 1 Then the magnetic particle for being coated with Streptavidin is added in conjunction with specimen needle carcinomebryonic antigen molecule in Cea Monoclonal Antibodies, Immune complex is adsorbed to magnetic particle surface.No. 2 mixing temperature of reagent are added after taking out unbonded antibody and impurity in washing It educates, the Cea Monoclonal Antibodies and the carcinomebryonic antigen in above-mentioned immune complex of the alkali phosphatase enzyme mark in reagent 2 Molecule combines.Chemical substrate, alkaline phosphatase catalytic chemistry substrate hair is added after taking out unbonded antibody and impurity in washing Light measures relative luminous intensity.Luminous intensity in a certain range is directly proportional to carcinomebryonic antigen concentration, just by interpolation method It can be from the content for reading carcinomebryonic antigen in sample to be tested on standard curve.
Beneficial effects of the present invention: the kit of auxiliary detection sub-health population cancer base antigen prepared by the present invention uses The reaction pattern of double antibody sandwich method, high sensitivity is easy to operate, and no radiocontamination, low in cost, reaction process quickly may be used It leans on, realizes high-throughput detection and quantitative determination, advise the state of an illness of disease for sub-health population and broad-spectrum tumor screening provides a conjunction Suitable theoretical judgment.It the kit alignment product, quality-control product, reagent 1, reagent 2, Magneto separate reagent, chemical substrate and washes Washing liquid etc. is the optimization formula under the reaction system, fully ensures that validity period and detection performance.
Specific embodiment
The present invention will be further described combined with specific embodiments below.
Embodiment 1
A kind of kit of auxiliary detection sub-health population cancer base antigen, consists of the following compositions: carcinomebryonic antigen calibration Product, cancer base antigen quality-control product, reagent 1, reagent 2, Magneto separate reagent, chemical substrate and cleaning solution.
The preparation method of the kit of above-mentioned auxiliary detection sub-health population cancer base antigen, carries out in accordance with the following steps:
(1) carcinomebryonic antigen calibration object is prepared: by potassium dihydrogen phosphate powder 0.3g, disodium hydrogen phosphate powder 1.5g, sodium chloride Powder 8g, potassium chloride powder 0.3g, the Proclin300 solution 0.15g of concentration 98%, deionized water 800g are added to the container, It is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.3, by bovine serum albumin(BSA) 32g is added to the container, and is stirred well to and is completely dissolved, and the phosphoric acid of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture Buffer salt solution, by the phosphate buffered saline solution of cancer base antigen bovine serum albumin(BSA) be diluted to each concentration point be 0,5,25, 100,500 and 1000ng/mL；
(2) cancer base antigen quality-control product is prepared: cancer base antigen is dilute with the phosphate buffered saline solution of above-mentioned bovine serum albumin(BSA) Releasing to each concentration point is 10ng/mL and 100ng/mL；
(3) reagent preparation 1: by tromethamine powder 8g, sodium chloride powder 4g, the Proclin300 of concentration 98% Solution 0.15g, deionized water 800g, is added to the container, and is stirred well to and is completely dissolved, and the salt of concentration 36%~38% is added PH value is adjusted to 7.3 and is added to the container bovine serum albumin(BSA) 4g, is stirred well to and be completely dissolved by sour 0.5g, with 0.3 μ of aperture Tris buffer 1 of bovine serum albumin(BSA) is obtained after the filter filtering of m, it is anti-that conventional method prepares carcinomebryonic antigen monoclonal The solution of body --- biotin conjugate will be resisted with the Tris buffer 1 of bovine serum albumin(BSA) containing carcinomebryonic antigen monoclonal The solution of body --- biotin conjugate is diluted to 0.2 μ g/mL, obtains reagent 1；
(4) reagent preparation 2: by 4- hydroxyethyl piperazineethanesulfonic acid powder 5g, sodium chloride powder 0.65g, zinc chloride powder 0.075g, container is added in magnesium chloride powder 0.075g, Proclin300 the solution 0.15g, deionized water 800g of concentration 98% In, it is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.7, ox blood is pure Albumen 4g is added to the container, and is stirred well to and is completely dissolved, and obtains bovine serum albumin(BSA) after being filtered with 0.3 μm of the filter in aperture Buffer 2, Cea Monoclonal Antibodies --- the solution of alkaline phosphatase attachment uses cow's serum for conventional method preparation Buffer 2 of albumin will contain Cea Monoclonal Antibodies --- and the solution of alkaline phosphatase attachment is diluted to 0.06 μ g/mL obtains reagent 2；
(5) it prepares Magneto separate reagent: tromethamine powder 8g, sodium chloride powder 6.5g, deionized water 800g is added In container, it is stirred well to and is completely dissolved, the Proclin300 of bovine serum albumin(BSA) 4g, cow's serum 40g, concentration 98% is molten Liquid 0.15g is added to the container, and is stirred well to and is completely dissolved, and the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 8.0, Tris buffer 3 of bovine serum albumin(BSA) are obtained after being filtered with 0.3 μm of the filter in aperture, conventional method is prepared magnetic micro- Grain --- solution of Streptavidin attachment will contain magnetic particle with Tris buffer 3 of bovine serum albumin(BSA) --- The solution of Streptavidin attachment is diluted to 0.5ng/mL, obtains Magneto separate reagent；
(6) chemical substrate is prepared: by tromethamine powder 20g, disodium ethylene diamine tetraacetate powder 20g, sodium chloride powder Last 18g, lauryl sodium sulfate 0.075g, glycerine 40g, sodium sulfite 0.075g, the Proclin300 solution of concentration 98% 0.15g, deionized water 800g are added to the container, are stirred well to and are completely dissolved, and the hydrochloric acid of concentration 36%~38% is added The pH value of solution is adjusted to 9.3 by 0.5g, and dioxane is added under light protected environment after being filtered with 0.3 μm of the filter in aperture Object 0.4g is closed, being configured to concentration is 0.5mg/mL, obtains chemical substrate；
(7) cleaning solution is prepared: by tromethamine powder 8g, sodium chloride powder 6.5g, polyoxyethylene sorbitan list Laurate powder 4g, Triton X-100 4g, deionized water 800g are added to the container, are stirred well to completely molten Solution is added the hydrochloric acid 0.5g of concentration 36%~38%, the pH value of solution is adjusted to 7.7, after being filtered with 0.3 μm of the filter in aperture Obtain cleaning solution.
Embodiment 2
A kind of kit of auxiliary detection sub-health population cancer base antigen, consists of the following compositions: carcinomebryonic antigen calibration Product, cancer base antigen quality-control product, reagent 1, reagent 2, Magneto separate reagent, chemical substrate and cleaning solution.
The preparation method of the kit of above-mentioned auxiliary detection sub-health population cancer base antigen, carries out in accordance with the following steps:
(1) carcinomebryonic antigen calibration object is prepared: by potassium dihydrogen phosphate powder 0.2g, disodium hydrogen phosphate powder 1g, sodium chloride powder Last 7g, potassium chloride powder 0.2g, the Proclin300 solution 0.1g of concentration 98%, deionized water 700g are added to the container, sufficiently Stirring is added the hydrochloric acid 0.1g of concentration 36%~38%, pH value is adjusted to 7.4, by bovine serum albumin(BSA) 30g to being completely dissolved It is added to the container, is stirred well to and is completely dissolved, the phosphoric acid that bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture is slow Rush salting liquid, by the phosphate buffered saline solution of cancer base antigen bovine serum albumin(BSA) be diluted to each concentration point be 0,5,25,100, 500 and 1000ng/mL；
(2) cancer base antigen quality-control product is prepared: cancer base antigen is dilute with the phosphate buffered saline solution of above-mentioned bovine serum albumin(BSA) Releasing to each concentration point is 10ng/mL and 100ng/mL；
(3) reagent preparation 1: by tromethamine powder 6g, sodium chloride powder 3g, the Proclin300 of concentration 98% Solution 0.1g, deionized water 700g, is added to the container, and is stirred well to and is completely dissolved, and the hydrochloric acid of concentration 36%~38% is added PH value is adjusted to 7.5 by 0.1g, and bovine serum albumin(BSA) 3g is added to the container, is stirred well to and is completely dissolved, with 0.3 μm of aperture Filter filtering after Tris buffer 1 of bovine serum albumin(BSA), conventional method prepares Cea Monoclonal Antibodies --- The solution of biotin conjugate will contain Cea Monoclonal Antibodies with Tris buffer 1 of bovine serum albumin(BSA) --- The solution of biotin conjugate is diluted to 0.1 μ g/mL, obtains reagent 1；
(4) reagent preparation 2: by 4- hydroxyethyl piperazineethanesulfonic acid powder 4g, sodium chloride powder 5g, zinc chloride powder 0.05g, magnesium chloride powder 0.05g, the Proclin300 solution 0.1g of concentration 98%, deionized water 700g are added to the container, It is stirred well to and is completely dissolved, the hydrochloric acid 0.1g of concentration 36%~38% is added, pH value is adjusted to 8.0, by bovine serum albumin(BSA) 3g is added to the container, and is stirred well to and is completely dissolved, and the buffering of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture Liquid 2, Cea Monoclonal Antibodies --- the solution of alkaline phosphatase attachment uses bovine serum albumin for conventional method preparation White buffer 2 will contain Cea Monoclonal Antibodies --- and the solution of alkaline phosphatase attachment is diluted to 0.02 μ g/ ML obtains reagent 2；
(5) it prepares Magneto separate reagent: tromethamine powder 6g, sodium chloride powder 5g, deionized water 700g being added and held It in device, is stirred well to and is completely dissolved, by bovine serum albumin(BSA) 3g, cow's serum 30g, the Proclin300 solution of concentration 98% 0.1g is added to the container, and is stirred well to and is completely dissolved, and the hydrochloric acid 0.1g of concentration 36%~38% is added, pH value is adjusted to 8.1, Tris buffer 3 of bovine serum albumin(BSA) are obtained after being filtered with 0.3 μm of the filter in aperture, conventional method is prepared magnetic micro- Grain --- solution of Streptavidin attachment will contain magnetic particle with Tris buffer 3 of bovine serum albumin(BSA) --- The solution of Streptavidin attachment is diluted to 0.5ng/mL, obtains Magneto separate reagent；
(6) chemical substrate is prepared: by tromethamine powder 15g, disodium ethylene diamine tetraacetate powder 15g, sodium chloride powder Last 15g, lauryl sodium sulfate 0.05g, glycerine 35g, sodium sulfite 0.05g, the Proclin300 solution of concentration 98% 0.1g, deionized water 700g are added to the container, are stirred well to and are completely dissolved, and the hydrochloric acid 0.1g of concentration 36%~38% is added, The pH value of solution is adjusted to 9.5, dioxane compound is added under light protected environment after being filtered with 0.3 μm of the filter in aperture 0.2g, being configured to concentration is 0.5mg/mL, obtains chemical substrate；
(7) cleaning solution is prepared: by tromethamine powder 6g, sodium chloride powder 5g, polyoxyethylene sorbitan Dan Yue Cinnamic acid ester powder 3g, Triton X-100 3g, deionized water 700g are added to the container, are stirred well to and are completely dissolved, The hydrochloric acid 0.1g of concentration 36%~38% is added, the pH value of solution is adjusted to 8.0, must be washed after being filtered with 0.3 μm of the filter in aperture Wash liquid.
Embodiment 3
A kind of kit of auxiliary detection sub-health population cancer base antigen, consists of the following compositions: carcinomebryonic antigen calibration Product, cancer base antigen quality-control product, reagent 1, reagent 2, Magneto separate reagent, chemical substrate and cleaning solution.
The preparation method of the kit of above-mentioned auxiliary detection sub-health population cancer base antigen, carries out in accordance with the following steps:
(1) carcinomebryonic antigen calibration object is prepared: by potassium dihydrogen phosphate powder 0.4g, disodium hydrogen phosphate powder 2g, sodium chloride powder Last 9g, potassium chloride powder 0.4g, the Proclin300 solution 0.2g of concentration 98%, deionized water 900g are added to the container, sufficiently Stirring is added the hydrochloric acid 1g of concentration 36%~38%, pH value is adjusted to 7.2, bovine serum albumin(BSA) 34g is added to being completely dissolved Enter in container, be stirred well to and be completely dissolved, the phosphoric acid buffer of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture Salting liquid, by the phosphate buffered saline solution of cancer base antigen bovine serum albumin(BSA) be diluted to each concentration point be 0,5,25,100, 500 and 1000ng/mL；
(2) cancer base antigen quality-control product is prepared: cancer base antigen is dilute with the phosphate buffered saline solution of above-mentioned bovine serum albumin(BSA) Releasing to each concentration point is 10ng/mL and 100ng/mL；
(3) reagent preparation 1: by tromethamine powder 10g, sodium chloride powder 5g, the Proclin300 of concentration 98% Solution 0.2g, deionized water 900g, is added to the container, and is stirred well to and is completely dissolved, and the hydrochloric acid of concentration 36%~38% is added PH value is adjusted to 7.0 by 1g, and bovine serum albumin(BSA) 5g is added to the container, is stirred well to and is completely dissolved, with 0.3 μm of aperture Tris buffer 1 of bovine serum albumin(BSA) is obtained after filter filtering, conventional method prepares Cea Monoclonal Antibodies --- it is raw The solution of object element attachment will contain Cea Monoclonal Antibodies with Tris buffer 1 of bovine serum albumin(BSA) --- and it is raw The solution of object element attachment is diluted to 0.3 μ g/mL, obtains reagent 1；
(4) reagent preparation 2: by 4- hydroxyethyl piperazineethanesulfonic acid powder 6g, sodium chloride powder 8g, zinc chloride powder 0.1g, magnesium chloride powder 0.1g, the Proclin300 solution 0.2g of concentration 98%, deionized water 900g are added to the container, sufficiently Stirring is added the hydrochloric acid 1g of concentration 36%~38%, pH value is adjusted to 7.5, bovine serum albumin(BSA) 5g is added to being completely dissolved It in container, is stirred well to and is completely dissolved, buffer 2 of bovine serum albumin(BSA) are obtained after being filtered with 0.3 μm of the filter in aperture, Conventional method prepares Cea Monoclonal Antibodies --- the solution of alkaline phosphatase attachment, with delaying for bovine serum albumin(BSA) Fliud flushing 2 will contain Cea Monoclonal Antibodies --- and the solution of alkaline phosphatase attachment is diluted to 0.1 μ g/mL, must try Agent 2；
(5) it prepares Magneto separate reagent: tromethamine powder 10g, sodium chloride powder 8g, deionized water 900g is added In container, it is stirred well to and is completely dissolved, the Proclin300 of bovine serum albumin(BSA) 5g, cow's serum 50g, concentration 98% is molten Liquid 0.2g is added to the container, and is stirred well to and is completely dissolved, and the hydrochloric acid 1g of concentration 36%~38% is added, pH value is adjusted to 7.9, Tris buffer 3 of bovine serum albumin(BSA) are obtained after being filtered with 0.3 μm of the filter in aperture, conventional method is prepared magnetic micro- Grain --- solution of Streptavidin attachment will contain magnetic particle with Tris buffer 3 of bovine serum albumin(BSA) --- The solution of Streptavidin attachment is diluted to 0.5ng/mL, obtains Magneto separate reagent；
(6) chemical substrate is prepared: by tromethamine powder 25g, disodium ethylene diamine tetraacetate powder 25g, sodium chloride powder Last 20g, lauryl sodium sulfate 0.1g, glycerine 45g, sodium sulfite 0.1g, the Proclin300 solution of concentration 98% 0.2g, deionized water 900g are added to the container, are stirred well to and are completely dissolved, and the hydrochloric acid 1g of concentration 36%~38% is added, will The pH value of solution is adjusted to 9.2, and dioxane compound is added under light protected environment after being filtered with 0.3 μm of the filter in aperture 0.6g, being configured to concentration is 0.5mg/mL, obtains chemical substrate；
(7) cleaning solution is prepared: by tromethamine powder 10g, sodium chloride powder 8g, polyoxyethylene sorbitan list Laurate powder 5g, Triton X-100 5g, deionized water 900g are added to the container, are stirred well to completely molten Solution is added the hydrochloric acid 1g of concentration 36%~38%, the pH value of solution is adjusted to 7.5, after being filtered with 0.3 μm of the filter in aperture Cleaning solution.
Embodiment 4
A kind of kit of auxiliary detection sub-health population cancer base antigen, consists of the following compositions: carcinomebryonic antigen calibration Product, cancer base antigen quality-control product, reagent 1, reagent 2, Magneto separate reagent, chemical substrate and cleaning solution.
The preparation method of the kit of above-mentioned auxiliary detection sub-health population cancer base antigen, carries out in accordance with the following steps:
(1) carcinomebryonic antigen calibration object is prepared: by potassium dihydrogen phosphate powder 0.3g, disodium hydrogen phosphate powder 1.5g, sodium chloride Powder 8g, potassium chloride powder 0.3g, the Proclin300 solution 0.15g of concentration 98%, deionized water 800g are added to the container, It is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.3, by bovine serum albumin(BSA) 32g is added to the container, and is stirred well to and is completely dissolved, and the phosphoric acid of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture Buffer salt solution, by the phosphate buffered saline solution of cancer base antigen bovine serum albumin(BSA) be diluted to each concentration point be 0,5,25, 100,500 and 1000ng/mL；
(2) cancer base antigen quality-control product is prepared: cancer base antigen is dilute with the phosphate buffered saline solution of above-mentioned bovine serum albumin(BSA) Releasing to each concentration point is 10ng/mL and 100ng/mL；
(3) reagent preparation 1: by tromethamine powder 8g, sodium chloride powder 4g, the Proclin300 of concentration 98% Solution 0.15g, deionized water 800g, is added to the container, and is stirred well to and is completely dissolved, and the salt of concentration 36%~38% is added PH value is adjusted to 7.3 and is added to the container, is stirred well to and is completely dissolved bovine serum albumin(BSA) 4g, casein 4g by sour 0.5g, Tris buffer 1 of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture, conventional method prepares carcinomebryonic antigen list The solution of clonal antibody --- biotin conjugate will contain carcinomebryonic antigen list with the Tris buffer 1 of bovine serum albumin(BSA) The solution of clonal antibody --- biotin conjugate is diluted to 0.2 μ g/mL, obtains reagent 1；
(4) reagent preparation 2: by 4- hydroxyethyl piperazineethanesulfonic acid powder 5g, sodium chloride powder 0.65g, zinc chloride powder 0.075g, container is added in magnesium chloride powder 0.075g, Proclin300 the solution 0.15g, deionized water 800g of concentration 98% In, it is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.7, ox blood is pure Albumen 4g, casein 4g are added to the container, are stirred well to and are completely dissolved, and obtain cow's serum after being filtered with 0.3 μm of the filter in aperture The buffer of albumin 2, conventional method prepare Cea Monoclonal Antibodies --- the solution of alkaline phosphatase attachment, Cea Monoclonal Antibodies will be contained with buffer 2 of bovine serum albumin(BSA) --- the solution of alkaline phosphatase attachment It is diluted to 0.06 μ g/mL, obtains reagent 2；
(5) it prepares Magneto separate reagent: tromethamine powder 8g, sodium chloride powder 6.5g, deionized water 800g is added In container, it is stirred well to and is completely dissolved, the Proclin300 of bovine serum albumin(BSA) 4g, cow's serum 40g, concentration 98% is molten Liquid 0.15g, casein 4g are added to the container, are stirred well to and are completely dissolved, and the hydrochloric acid 0.5g of concentration 36%~38% is added, PH value is adjusted to 8.0, Tris buffer 3 of bovine serum albumin(BSA), conventional method are obtained after being filtered with 0.3 μm of the filter in aperture Magnetic particle --- the solution of Streptavidin attachment is prepared, magnetic will be contained with Tris buffer 3 of bovine serum albumin(BSA) Particle --- the solution of Streptavidin attachment is diluted to 0.5ng/mL to property, obtains Magneto separate reagent；
(6) chemical substrate is prepared: by tromethamine powder 20g, disodium ethylene diamine tetraacetate powder 20g, sodium chloride powder Last 18g, lauryl sodium sulfate 0.075g, glycerine 40g, sodium sulfite 0.075g, the Proclin300 solution of concentration 98% 0.15g, deionized water 800g are added to the container, are stirred well to and are completely dissolved, and the hydrochloric acid of concentration 36%~38% is added The pH value of solution is adjusted to 9.3 by 0.5g, and dioxane is added under light protected environment after being filtered with 0.3 μm of the filter in aperture Object 0.4g is closed, being configured to concentration is 0.5mg/mL, obtains chemical substrate；
(7) cleaning solution is prepared: by tromethamine powder 8g, sodium chloride powder 6.5g, polyoxyethylene sorbitan list Laurate powder 4g, Triton X-100 4g, deionized water 800g are added to the container, are stirred well to completely molten Solution is added the hydrochloric acid 0.5g of concentration 36%~38%, the pH value of solution is adjusted to 7.7, after being filtered with 0.3 μm of the filter in aperture Obtain cleaning solution.
Embodiment 5
A kind of kit of auxiliary detection sub-health population cancer base antigen, consists of the following compositions: carcinomebryonic antigen calibration Product, cancer base antigen quality-control product, reagent 1, reagent 2, Magneto separate reagent, chemical substrate and cleaning solution.
The preparation method of the kit of above-mentioned auxiliary detection sub-health population cancer base antigen, carries out in accordance with the following steps:
(1) carcinomebryonic antigen calibration object is prepared: by potassium dihydrogen phosphate powder 0.3g, disodium hydrogen phosphate powder 1.5g, sodium chloride Powder 8g, potassium chloride powder 0.3g, the Proclin300 solution 0.15g of concentration 98%, deionized water 800g are added to the container, It is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.3, by bovine serum albumin(BSA) 32g is added to the container, and is stirred well to and is completely dissolved, and the phosphoric acid of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture Buffer salt solution, by the phosphate buffered saline solution of cancer base antigen bovine serum albumin(BSA) be diluted to each concentration point be 0,5,25, 100,500 and 1000ng/mL；
(2) cancer base antigen quality-control product is prepared: cancer base antigen is dilute with the phosphate buffered saline solution of above-mentioned bovine serum albumin(BSA) Releasing to each concentration point is 10ng/mL and 100ng/mL；
(3) reagent preparation 1: by tromethamine powder 8g, sodium chloride powder 4g, the Proclin300 of concentration 98% Solution 0.15g, deionized water 800g, is added to the container, and is stirred well to and is completely dissolved, and the salt of concentration 36%~38% is added PH value is adjusted to 7.3 and bovine serum albumin(BSA) 4g, N- hydroxysuccinimide powder 4g is added to the container, is sufficiently stirred by sour 0.5g It mixes to being completely dissolved, Tris buffer 1 of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture, conventional method is matched The solution of Cea Monoclonal Antibodies processed --- biotin conjugate will be contained with Tris buffer 1 of bovine serum albumin(BSA) There are Cea Monoclonal Antibodies --- the solution of biotin conjugate is diluted to 0.2 μ g/mL, obtains reagent 1；
(4) reagent preparation 2: by 4- hydroxyethyl piperazineethanesulfonic acid powder 5g, sodium chloride powder 0.65g, zinc chloride powder 0.075g, container is added in magnesium chloride powder 0.075g, Proclin300 the solution 0.15g, deionized water 800g of concentration 98% In, it is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.7, ox blood is pure Albumen 4g, N- hydroxysuccinimide powder 4g is added to the container, and is stirred well to and is completely dissolved, with 0.3 μm of the filter in aperture Buffer 2 of bovine serum albumin(BSA) are obtained after filtering, conventional method prepares Cea Monoclonal Antibodies --- alkaline phosphatase The solution of attachment will contain Cea Monoclonal Antibodies with buffer 2 of bovine serum albumin(BSA) --- alkaline phosphatase The solution of attachment is diluted to 0.06 μ g/mL, obtains reagent 2；
(5) it prepares Magneto separate reagent: tromethamine powder 8g, sodium chloride powder 6.5g, deionized water 800g is added In container, it is stirred well to and is completely dissolved, the Proclin300 of bovine serum albumin(BSA) 4g, cow's serum 40g, concentration 98% is molten Liquid 0.15g, N- hydroxysuccinimide powder 4g is added to the container, and is stirred well to and is completely dissolved, and addition concentration 36%~ 38% hydrochloric acid 0.5g, is adjusted to 8.0 for pH value, and the Tris that bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture is buffered Liquid 3, conventional method prepares magnetic particle --- the solution of Streptavidin attachment, slow with the Tris of bovine serum albumin(BSA) Fliud flushing 3 will contain magnetic particle --- and the solution of Streptavidin attachment is diluted to 0.5ng/mL, obtains Magneto separate reagent；
(6) chemical substrate is prepared: by tromethamine powder 20g, disodium ethylene diamine tetraacetate powder 20g, sodium chloride powder Last 18g, lauryl sodium sulfate 0.075g, glycerine 40g, sodium sulfite 0.075g, the Proclin300 solution of concentration 98% 0.15g, deionized water 800g are added to the container, are stirred well to and are completely dissolved, and the hydrochloric acid of concentration 36%~38% is added The pH value of solution is adjusted to 9.3 by 0.5g, and dioxane is added under light protected environment after being filtered with 0.3 μm of the filter in aperture Object 0.4g is closed, being configured to concentration is 0.5mg/mL, obtains chemical substrate；
(7) cleaning solution is prepared: by tromethamine powder 8g, sodium chloride powder 6.5g, polyoxyethylene sorbitan list Laurate powder 4g, Triton X-100 4g, deionized water 800g are added to the container, are stirred well to completely molten Solution is added the hydrochloric acid 0.5g of concentration 36%~38%, the pH value of solution is adjusted to 7.7, after being filtered with 0.3 μm of the filter in aperture Obtain cleaning solution.
Embodiment 6
A kind of kit of auxiliary detection sub-health population cancer base antigen, consists of the following compositions: carcinomebryonic antigen calibration Product, cancer base antigen quality-control product, reagent 1, reagent 2, Magneto separate reagent, chemical substrate and cleaning solution.
The preparation method of the kit of above-mentioned auxiliary detection sub-health population cancer base antigen, carries out in accordance with the following steps:
(1) carcinomebryonic antigen calibration object is prepared: by potassium dihydrogen phosphate powder 0.3g, disodium hydrogen phosphate powder 1.5g, sodium chloride Powder 8g, potassium chloride powder 0.3g, the Proclin300 solution 0.15g of concentration 98%, deionized water 800g are added to the container, It is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.3, by bovine serum albumin(BSA) 32g is added to the container, and is stirred well to and is completely dissolved, and the phosphoric acid of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture Buffer salt solution, by the phosphate buffered saline solution of cancer base antigen bovine serum albumin(BSA) be diluted to each concentration point be 0,5,25, 100,500 and 1000ng/mL；
(2) cancer base antigen quality-control product is prepared: cancer base antigen is dilute with the phosphate buffered saline solution of above-mentioned bovine serum albumin(BSA) Releasing to each concentration point is 10ng/mL and 100ng/mL；
(3) reagent preparation 1: by tromethamine powder 8g, sodium chloride powder 4g, the Proclin300 of concentration 98% Solution 0.15g, deionized water 800g, is added to the container, and is stirred well to and is completely dissolved, and the salt of concentration 36%~38% is added PH value is adjusted to 7.3 for bovine serum albumin(BSA) 4g, (Na by sour 0.5g2.3K0.7) (B6O10)(N O3) powder 4g is added to the container, It is stirred well to and is completely dissolved, Tris buffer 1 of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture, it is conventional Method prepares Cea Monoclonal Antibodies --- the solution of biotin conjugate, with the Tris buffer 1 of bovine serum albumin(BSA) Number containing Cea Monoclonal Antibodies --- the solution of biotin conjugate is diluted to 0.2 μ g/mL, obtains reagent 1；
(4) reagent preparation 2: by 4- hydroxyethyl piperazineethanesulfonic acid powder 5g, sodium chloride powder 0.65g, zinc chloride powder 0.075g, container is added in magnesium chloride powder 0.075g, Proclin300 the solution 0.15g, deionized water 800g of concentration 98% In, it is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.7, ox blood is pure Albumen 4g, (Na2.3K0.7)(B6O10)(N O3) powder 4g is added to the container, is stirred well to and is completely dissolved, with 0.3 μm of aperture Filter filtering after buffer 2 of bovine serum albumin(BSA), conventional method prepares Cea Monoclonal Antibodies --- alkalinity The solution of phosphatase attachment will contain Cea Monoclonal Antibodies with buffer 2 of bovine serum albumin(BSA) --- alkalinity The solution of phosphatase attachment is diluted to 0.06 μ g/mL, obtains reagent 2；
(5) it prepares Magneto separate reagent: tromethamine powder 8g, sodium chloride powder 6.5g, deionized water 800g is added In container, it is stirred well to and is completely dissolved, the Proclin300 of bovine serum albumin(BSA) 4g, cow's serum 40g, concentration 98% is molten Liquid 0.15g, (Na2.3K0.7)(B6O10)(N O3) powder 4g is added to the container, is stirred well to and is completely dissolved, concentration is added 36%~38% hydrochloric acid 0.5g, is adjusted to 8.0 for pH value, obtains bovine serum albumin(BSA) after being filtered with 0.3 μm of the filter in aperture Tris buffer 3, magnetic particle --- the solution of Streptavidin attachment uses bovine serum albumin(BSA) for conventional method preparation Tris buffer 3 will contain magnetic particle --- the solution of Streptavidin attachment is diluted to 0.5ng/mL, obtains magnetic point From reagent；
(6) chemical substrate is prepared: by tromethamine powder 20g, disodium ethylene diamine tetraacetate powder 20g, sodium chloride powder Last 18g, lauryl sodium sulfate 0.075g, glycerine 40g, sodium sulfite 0.075g, the Proclin300 solution of concentration 98% 0.15g, deionized water 800g are added to the container, are stirred well to and are completely dissolved, and the hydrochloric acid of concentration 36%~38% is added The pH value of solution is adjusted to 9.3 by 0.5g, and dioxane is added under light protected environment after being filtered with 0.3 μm of the filter in aperture Object 0.4g is closed, being configured to concentration is 0.5mg/mL, obtains chemical substrate；
(7) cleaning solution is prepared: by tromethamine powder 8g, sodium chloride powder 6.5g, polyoxyethylene sorbitan list Laurate powder 4g, Triton X-100 4g, deionized water 800g are added to the container, are stirred well to completely molten Solution is added the hydrochloric acid 0.5g of concentration 36%~38%, the pH value of solution is adjusted to 7.7, after being filtered with 0.3 μm of the filter in aperture Obtain cleaning solution.
Embodiment 7
A kind of kit of auxiliary detection sub-health population cancer base antigen, consists of the following compositions: carcinomebryonic antigen calibration Product, cancer base antigen quality-control product, reagent 1, reagent 2, Magneto separate reagent, chemical substrate and cleaning solution.
The preparation method of the kit of above-mentioned auxiliary detection sub-health population cancer base antigen, carries out in accordance with the following steps:
(1) carcinomebryonic antigen calibration object is prepared: by potassium dihydrogen phosphate powder 0.3g, disodium hydrogen phosphate powder 1.5g, sodium chloride Powder 8g, potassium chloride powder 0.3g, the Proclin300 solution 0.15g of concentration 98%, deionized water 800g are added to the container, It is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.3, by bovine serum albumin(BSA) 32g is added to the container, and is stirred well to and is completely dissolved, and the phosphoric acid of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture Buffer salt solution, by the phosphate buffered saline solution of cancer base antigen bovine serum albumin(BSA) be diluted to each concentration point be 0,5,25, 100,500 and 1000ng/mL；
(2) cancer base antigen quality-control product is prepared: cancer base antigen is dilute with the phosphate buffered saline solution of above-mentioned bovine serum albumin(BSA) Releasing to each concentration point is 10ng/mL and 100ng/mL；
(3) reagent preparation 1: by tromethamine powder 8g, the Proclin300 of sodium chloride powder 4g, concentration 98% are molten Liquid 0.15g, deionized water 800g, is added to the container, and is stirred well to and is completely dissolved, and the hydrochloric acid of concentration 36%~38% is added PH value is adjusted to 7.3 and is added to the container bovine serum albumin(BSA) 4g, Eudesmin powder 4g by 0.5g, is stirred well to completely molten Solution obtains Tris buffer 1 of bovine serum albumin(BSA) after being filtered with 0.3 μm of the filter in aperture, conventional method prepares carcinomebryonic antigen The solution of monoclonal antibody --- biotin conjugate will contain carcinomebryonic antigen with Tris buffer 1 of bovine serum albumin(BSA) The solution of monoclonal antibody --- biotin conjugate is diluted to 0.2 μ g/mL, obtains reagent 1；
(4) reagent preparation 2: by 4- hydroxyethyl piperazineethanesulfonic acid powder 5g, sodium chloride powder 0.65g, zinc chloride powder Container is added in 0.075g, magnesium chloride powder 0.075g, Proclin300 the solution 0.15g, deionized water 800g of concentration 98% In, it is stirred well to and is completely dissolved, the hydrochloric acid 0.5g of concentration 36%~38% is added, pH value is adjusted to 7.7, ox blood is pure Albumen 4g, Eudesmin powder 4g are added to the container, are stirred well to and are completely dissolved, and obtain ox after being filtered with 0.3 μm of the filter in aperture Sero-abluminous buffer 2, conventional method prepare Cea Monoclonal Antibodies --- alkaline phosphatase attachment it is molten Liquid will contain Cea Monoclonal Antibodies with buffer 2 of bovine serum albumin(BSA) --- alkaline phosphatase attachment it is molten Liquid is diluted to 0.06 μ g/mL, obtains reagent 2；
(5) it prepares Magneto separate reagent: tromethamine powder 8g, sodium chloride powder 6.5g, deionized water 800g is added In container, it is stirred well to and is completely dissolved, the Proclin300 of bovine serum albumin(BSA) 4g, cow's serum 40g, concentration 98% is molten Liquid 0.15g, Eudesmin powder 4g are added to the container, are stirred well to and are completely dissolved, and the hydrochloric acid of concentration 36%~38% is added PH value is adjusted to 8.0 by 0.5g, and Tris buffer 3 of bovine serum albumin(BSA) are obtained after being filtered with 0.3 μm of the filter in aperture, conventional Method prepares magnetic particle --- the solution of Streptavidin attachment, will be contained with Tris buffer 3 of bovine serum albumin(BSA) Be magnetic particle --- and the solution of Streptavidin attachment is diluted to 0.5ng/mL, obtains Magneto separate reagent；
(6) chemical substrate is prepared: by tromethamine powder 20g, disodium ethylene diamine tetraacetate powder 20g, sodium chloride powder Last 18g, lauryl sodium sulfate 0.075g, glycerine 40g, sodium sulfite 0.075g, the Proclin300 solution of concentration 98% 0.15g, deionized water 800g are added to the container, are stirred well to and are completely dissolved, and the hydrochloric acid of concentration 36%~38% is added The pH value of solution is adjusted to 9.3 by 0.5g, and dioxane is added under light protected environment after being filtered with 0.3 μm of the filter in aperture Object 0.4g is closed, being configured to concentration is 0.5mg/mL, obtains chemical substrate；
(7) cleaning solution is prepared: by tromethamine powder 8g, sodium chloride powder 6.5g, polyoxyethylene sorbitan list Laurate powder 4g, Triton X-100 4g, deionized water 800g are added to the container, are stirred well to completely molten Solution is added the hydrochloric acid 0.5g of concentration 36%~38%, the pH value of solution is adjusted to 7.7, after being filtered with 0.3 μm of the filter in aperture Obtain cleaning solution.
Experimental example 1:
1 batch is respectively taken according to the kit prepared in embodiment 1-7, measures the serum of basic, normal, high concentration respectively, 50 holes are flat Row measurement, obtains variation within batch coefficient, separately respectively takes 3 batches according to the kit prepared in embodiment 1-7, every a batch kit difference The serum of basic, normal, high concentration is measured, 50 holes are measured in parallel, interassay coefficient of variation is obtained, as a result referring to table 1:
The comparison of the variation within batch coefficient and interassay coefficient of variation of each experimental example of table 1
Note: * represents P < 0.05 compared with example 1 group
By table 1, it can be concluded that, the variation within batch coefficient of the measurement serum-concentration 3.5ng/mL of embodiment 1-3 is suitable, does not have The variation within batch coefficient of significant difference, the measurement serum-concentration 3.5ng/mL of embodiment 4-7 is substantially less than embodiment 1.Embodiment The variation within batch coefficient of 1-3, the measurement serum-concentration 30.6ng/mL of embodiment 5 are suitable, are not significantly different, embodiment 4, real The variation within batch coefficient for applying the measurement serum-concentration 30.6ng/mL of a 6-7 is substantially less than embodiment 1.The measurement of embodiment 1-3 The variation within batch coefficient of serum-concentration 50.3g/mL is suitable, is not significantly different, the measurement serum-concentration of embodiment 4-7 The variation within batch coefficient of 50.3ng/mL is substantially less than embodiment 1.The measurement serum-concentration 3.5ng/mL of embodiment 1-3 and The interassay coefficient of variation of 50.3ng/mL is suitable, is not significantly different, the measurement serum-concentration 3.5ng/mL's of embodiment 4-7 Interassay coefficient of variation is substantially less than embodiment 1.The variation within batch coefficient phase of the measurement serum-concentration 30.6ng/mL of embodiment 1-4 When being not significantly different, the variation within batch coefficient of the measurement serum-concentration 30.6ng/mL of embodiment 5-7 is substantially less than embodiment 1。
Experimental example 2:
Respectively take 1 batch according to the kit prepared in embodiment 1-7, use the zero-dose calibration object of calibration object STD-A point as Sample is detected, and replication 50 times, obtains the relative luminous intensity RLU value of 50 measurement result calibration object STD-A points, Its average value (M) and standard deviation (SD) are calculated, obtains relative luminous intensity RLU corresponding to the M+2SD of calibration object STD-A point Value, uses the calibration object of calibration object STD-B point to be detected as sample, replication 50 times, obtains 50 measurement result calibrations The relative luminous intensity RLU value of product STD-B point simultaneously calculates average value M ', according to the zero-dose calibration object of STD-A point and calibration The mean value result of concentration and relative luminous intensity RLU value between product STD-B point carries out two o'clock regression fit and obtains first power RLU value corresponding to the M+2SD of calibration object STD-A point is brought into above-mentioned equation, finds out corresponding concentration value by journey, as empty White limit, as a result referring to table 2:
The comparison of the blank limit of each experimental example of table 2
Note: * represents P < 0.05 compared with example 1 group
By table 2, it can be concluded that, the blank limit of embodiment 1-3 quite, is not significantly different, the blank limit of embodiment 4-7 Substantially less than embodiment 1 illustrates that the sensitivity of embodiment 4-7 is higher.
Experimental example 3:
Accuracy refers to that measured value obtains degree close to true value, is usually indicated with the rate of recovery, according to preparing in embodiment 1-7 Kit respectively take 1 batch, separately take clinical definite value serum, concentration 8.38ng/mL adds certain density reality thereto respectively A standard items for 1-7 kit are applied, and measure the concentration value of sample after 100 mixing, calculate measurement average value and the rate of recovery, As a result referring to table 3:
The rate of recovery of each experimental example of table 3
Note: * represents P < 0.05 compared with example 1 group
By table 3, it can be concluded that, the rate of recovery of embodiment 1-3 is suitable, is not significantly different, and the rate of recovery of embodiment 4-7 is aobvious It writes and is higher than embodiment 1, illustrate that the accuracy of embodiment 4-7 is higher.
Experimental example 4:
1 batch is respectively taken according to the kit prepared in embodiment 1-7, respectively taking a g carcinomebryonic antigen is 0 sample, and first tire is added Albumin A FP antigen concentration is 100ng/mL, is detected using the kit prepared in embodiment 1-7, and cancer embryo in sample is detected Content, measurement 100 times and calculates relative light unit RLU and concentration, as a result referring to table 4:
The Evaluation on specificity of each experimental example of table 4
Note: * represents P < 0.05 compared with example 1 group
By table 4, it can be concluded that, the measurement result mean value of embodiment 1-3 is suitable, is not significantly different, the survey of embodiment 4-7 Determine result mean value and is substantially less than embodiment 1.
Experimental example 5:
1 batch is respectively taken according to the kit prepared in embodiment 1-7, it will be close to the height of the range of linearity upper limit (1000ng/mL) Value sample is diluted at least six kinds of concentration according to a certain percentage, and wherein the sample of low value concentration must be close under the range of linearity Limit repeats to detect 3 times, calculates its average value to the sample standard deviation of each concentration, by result average value and dilution ratio minimum two Multiplication carries out straight line fitting, and calculates linearly dependent coefficient r, as a result referring to table 5:
It is evaluated after the dilution of each experimental example of table 5
It can be concluded that, after the dilution of embodiment 1-7 quite, it is not significantly different by table 5, illustrates that the range of linearity is good.
Experimental example 6:
1 batch is respectively taken according to the kit prepared in embodiment 1-7, carries out 4 DEG C respectively to kit 12 months and 37 DEG C 7 It accelerated stability experiment, the results showed that the variation of kit standard product luminous intensity criticizes interior and betweenrun precision, is accurate The indicator deviations such as degree are little, and within normal range (NR), kit validity period was up to 12 months.

Claims (10)

1. a kind of kit of auxiliary detection sub-health population cancer base antigen, which is characterized in that the kit includes:
1) carcinomebryonic antigen calibration object, the phosphate buffered saline solution containing carcinomebryonic antigen and bovine serum albumin(BSA), the bovine serum albumin White phosphate buffered saline solution includes following component: bovine serum albumin(BSA) 30-34g, potassium dihydrogen phosphate powder 0.2-0.4g, phosphoric acid Disodium hydrogen powder 1-2g, sodium chloride powder 7-9g, potassium chloride powder 0.2-0.4g, the hydrochloric acid 0.1-1mL of concentration 36%~38%, Proclin300 the solution 0.1-0.2mL, deionized water 700-900mL of concentration 98%；The carcinomebryonic antigen calibration object is 6 water Flat liquid calibration object, the concentration of carcinomebryonic antigen is respectively 0,5,25,100,500 and in 6 horizontal calibration objects 1000ng/mL, pH 7.2-7.4；
2) cancer base antigen quality-control product, the phosphate buffered saline solution containing carcinomebryonic antigen and bovine serum albumin(BSA), the bovine serum albumin White phosphate buffered saline solution is the phosphate buffered saline solution of the bovine serum albumin(BSA) of the carcinomebryonic antigen calibration object, the cancer embryo Antigen quality-control product is 2 horizontal liquid calibration objects, and the target value concentration of carcinomebryonic antigen is in 2 horizontal liquid quality controls 10ng/mL and 100ng/mL, pH 7.2-7.4；
3) reagent 1, the Tris buffer of Cea Monoclonal Antibodies and bovine serum albumin(BSA) containing biotin labeling 1, Tris buffer 1 of the bovine serum albumin(BSA) includes following component, bovine serum albumin(BSA) 3-5g, tromethamine powder 6- 10g, sodium chloride powder 3-5g, the hydrochloric acid 0.1-1mL of concentration 36%~38%, the Proclin300 solution 0.1- of concentration 98% 0.2mL, deionized water 700-900mL；
4) reagent 2, the buffer 2 of Cea Monoclonal Antibodies and bovine serum albumin(BSA) containing alkali phosphatase enzyme mark Number, buffer 2 of the bovine serum albumin(BSA) include following component, 4- hydroxyethyl piperazineethanesulfonic acid powder 4-6g, sodium chloride Powder 5-8g, bovine serum albumin(BSA) 3-5g, zinc chloride powder 0.05-0.1g, magnesium chloride powder 0.05-0.1g, concentration 36%~ 38% hydrochloric acid 0.1-1mL, Proclin300 the solution 0.1-0.2mL, deionized water 700-900mL of concentration 98%；
5) Magneto separate reagent, the Tris buffer of magnetic particle and bovine serum albumin(BSA) containing marked by streptavidin 3, institute Tris buffer 3 for stating bovine serum albumin(BSA) include following component, bovine serum albumin(BSA) 3-5g, cow's serum 30-50g, amino Butantriol powder 6-10g, sodium chloride powder 5-8g, the hydrochloric acid 0.1-1mL of concentration 36%~38%, concentration 98% Proclin300 solution 0.1-0.2mL, deionized water 700-900mL；
6) chemical substrate, the chemical substrate include following component, tromethamine powder 15-25g, disodium ethylene diamine tetraacetate Powder 15-25g, sodium chloride powder 15-20g, dioxane compound 0.2-0.6g, lauryl sodium sulfate 0.05- 0.1g, glycerine 35-45g, sodium sulfite 0.05-0.1g, the Proclin300 solution 0.1-0.2mL of concentration 98%, deionization Water 700-900mL；
7) cleaning solution, the cleaning solution include following component, tromethamine powder 6-10g, sodium chloride powder 5-8g, polyoxy second Alkene sorbitan mono-laurate powder 3-5g, Triton X-100 3-5g, the hydrochloric acid of concentration 36%~38% 0.1-1mL, deionized water 700-900mL, the pH value of the cleaning solution are 7.5-8.0.
2. the kit of auxiliary detection sub-health population cancer base antigen according to claim 1, which is characterized in that the cancer Embryonal antigen calibration object, the carcinomebryonic antigen quality-control product, the reagent 1, the reagent 2, the Magneto separate reagent, describedization The storage temperature for learning substrate is 2-8 DEG C, and the storage temperature of the cleaning solution is 10-30 DEG C of room temperature, and the kit avoids sunlight Direct projection.
3. the kit of auxiliary detection sub-health population cancer base antigen according to claim 1, which is characterized in that the examination The concentration of the Cea Monoclonal Antibodies of biotin labeling is 0.1-0.3 μ g/mL, pH value 7.0-7.5 in agent 1, described The concentration of the Cea Monoclonal Antibodies of No. 2 alkaline phosphatases of reagent label is 0.02-0.1 μ g/mL, pH value 7.5- 8.0, the concentration of the Magneto separate reagent is 0.5ng/mL, and pH value 7.9-8.1, the diameter of the magnetic particle is 0.5-3.5 μ M, kernel are ferroso-ferric oxide, and surface is wrapped in the polymer containing carboxyl, dioxane chemical combination in the chemical substrate The concentration of object is 0.5mg/mL, pH value 9.2-9.5.
4. the kit of auxiliary detection sub-health population cancer base antigen according to claim 1, which is characterized in that the ox Sero-abluminous Tris buffer 1, the Tris of the buffer of the bovine serum albumin(BSA) 2 and the bovine serum albumin(BSA) Casein 3-5g can also be added in buffer 3.
5. the kit of auxiliary detection sub-health population cancer base antigen according to claim 1, which is characterized in that the ox Sero-abluminous Tris buffer 1, the buffer of the bovine serum albumin(BSA) 2, the Tris of the bovine serum albumin(BSA) N- hydroxysuccinimide powder 3-5g can also be added in buffer 3.
6. the kit of auxiliary detection sub-health population cancer base antigen according to claim 1, which is characterized in that the ox Sero-abluminous Tris buffer 1, the buffer of the bovine serum albumin(BSA) 2, the Tris of the bovine serum albumin(BSA) (Na can also be added in buffer 32.3K0.7)(B6O10)(NO3) powder 3-5g.
7. the preparation method of the kit of auxiliary detection sub-health population cancer base antigen according to claim 1, feature It is, carries out in accordance with the following steps:
1) carcinomebryonic antigen calibration object is prepared: by potassium dihydrogen phosphate powder 0.2-0.4g, disodium hydrogen phosphate powder 1-2g, sodium chloride powder Last 7-9g, potassium chloride powder 0.2-0.4g, Proclin300 the solution 0.1-0.2mL, deionized water 700-900mL of concentration 98% It is added to the container, is stirred well to and is completely dissolved, the hydrochloric acid 0.1-1mL of concentration 36%~38% is added, pH value is adjusted to 7.2- 7.4, bovine serum albumin(BSA) 30-34g is added to the container, is stirred well to and is completely dissolved, after being filtered with 0.3 μm of the filter in aperture The phosphate buffered saline solution for obtaining bovine serum albumin(BSA), the phosphate buffered saline solution of cancer base antigen bovine serum albumin(BSA) is diluted to Each concentration point is 0,5,25,100,500 and 1000ng/mL；
2) it prepares cancer base antigen quality-control product: cancer base antigen is diluted to respectively with the phosphate buffered saline solution of above-mentioned bovine serum albumin(BSA) Concentration point is 10ng/mL and 100ng/mL；
3) reagent preparation 1: by tromethamine powder 6-10g, the Proclin300 of sodium chloride powder 3-5g, concentration 98% are molten Liquid 0.1-0.2mL, deionized water 700-900mL, is added to the container, and is stirred well to and is completely dissolved, and addition concentration 36%~ 38% hydrochloric acid 0.1-1mL, is adjusted to 7.0-7.5 for pH value, and bovine serum albumin(BSA) 3-5g is added to the container, has been stirred well to Fully dissolved obtains Tris buffer 1 of bovine serum albumin(BSA) after being filtered with 0.3 μm of the filter in aperture, conventional method prepares cancer embryo The solution of antigen monoclonal antibody --- biotin conjugate will contain cancer embryo with the Tris buffer 1 of bovine serum albumin(BSA) The solution of antigen monoclonal antibody --- biotin conjugate is diluted to 0.1-0.3 μ g/mL, obtains reagent 1；
4) reagent preparation 2: by 4- hydroxyethyl piperazineethanesulfonic acid powder 4-6g, sodium chloride powder 5-8g, zinc chloride powder 0.05- 0.1g, magnesium chloride powder 0.05-0.1g, Proclin300 the solution 0.1-0.2mL, deionized water 700-900mL of concentration 98% It is added to the container, is stirred well to and is completely dissolved, the hydrochloric acid 0.1-1mL of concentration 36%~38% is added, pH value is adjusted to 7.5- 8.0, bovine serum albumin(BSA) 3-5g is added to the container, is stirred well to and is completely dissolved, after being filtered with 0.3 μm of the filter in aperture The buffer of bovine serum albumin(BSA) 2, conventional method prepare Cea Monoclonal Antibodies --- alkaline phosphatase attachment Solution, will be molten containing Cea Monoclonal Antibodies-alkaline phosphatase attachment with the buffer 2 of bovine serum albumin(BSA) Liquid is diluted to 0.02-0.1 μ g/mL, obtains reagent 2；
5) it prepares Magneto separate reagent: tromethamine powder 6-10g, sodium chloride powder 5-8g, deionized water 700-900mL is added Enter in container, is stirred well to and is completely dissolved, by bovine serum albumin(BSA) 3-5g, cow's serum 30-50g, concentration 98% Proclin300 solution 0.1-0.2mL is added to the container, and is stirred well to and is completely dissolved, and the hydrochloric acid of concentration 36%~38% is added PH value is adjusted to 7.9-8.1 by 0.1-1mL, and the Tris buffer 3 of bovine serum albumin(BSA) is obtained after being filtered with 0.3 μm of the filter in aperture Number, conventional method prepares magnetic particle --- the solution of Streptavidin attachment, with the Tris buffer 3 of bovine serum albumin(BSA) Number containing magnetic particle --- the solution of Streptavidin attachment is diluted to 0.5ng/mL, obtains Magneto separate reagent；
6) chemical substrate is prepared: by tromethamine powder 15-25g, disodium ethylene diamine tetraacetate powder 15-25g, sodium chloride powder Last 15-20g, lauryl sodium sulfate 0.05-0.1g, glycerine 35-45g, sodium sulfite 0.05-0.1g, concentration 98% Proclin300 solution 0.1-0.2mL, deionized water 700-900mL are added to the container, are stirred well to and are completely dissolved, and are added dense The hydrochloric acid 0.1-1mL of degree 36%~38%, is adjusted to 9.2-9.5 for the pH value of solution, is protected from light after being filtered with 0.3 μm of the filter in aperture Dioxane compound 0.2-0.6g is added under environment, being configured to concentration is 0.5mg/mL, obtains chemical substrate；
7) cleaning solution is prepared: by tromethamine powder 6-10g, sodium chloride powder 5-8g, polyoxyethylene sorbitan Dan Yue Cinnamic acid ester powder 3-5g, Triton X-100 3-5g, deionized water 700-900mL are added to the container, are stirred well to It is completely dissolved, the hydrochloric acid 0.1-1mL of concentration 36%~38% is added, the pH value of solution is adjusted to 7.5-8.0, with 0.3 μm of aperture Filter filtering after cleaning solution.
8. the preparation method of the kit of auxiliary detection sub-health population cancer base antigen according to claim 7, feature It is, the step (3), the step (4), casein 3-5g or N- maloyl can be also added in the step (5) Imines powder 3-5g.
9. the preparation method of the kit of auxiliary detection sub-health population cancer base antigen according to claim 7, feature It is, the step (3), the step (4), (Na can be also added in the step (5)2.3K0.7)(B6O10)(NO3) powder 3- 5g。
10. the detection method of the kit of auxiliary detection sub-health population cancer base antigen according to claim 1, feature It is, this method comprises the following steps:
1) plus 10 μ L cancer base antigen calibration objects, quality-control product or sample to be tested are into detection pipe；
2) the cancer base antigenic agents 1 of 50 μ L are added into detection pipe described in step 1), after mixing, 37 ± 0.5 DEG C incubate 10 points Clock；
3) 50 μ L Magneto separate reagents are added into detection pipe described in step 2), after mixing, 37 ± 0.5 DEG C are incubated 5 minutes, carry out magnetic Separate supernatant；
4) cleaning solution of 500 μ L is added into detection pipe described in step 3), after mixing, carries out Magneto separate and removes supernatant；
5) it repeats twice of step 4)；
6) 50 μ L reagents 2 are added into detection pipe described in step 5), after mixing, 37 ± 0.5 DEG C are incubated 7 minutes, carry out magnetic point It leaves away supernatant；
7) cleaning solution of 500 μ L is added into detection pipe described in step 6), after mixing, carries out Magneto separate and removes supernatant；
8) it repeats twice of step 4)；
9) 200 μ L chemical substrates are added into detection pipe described in step 8), luminous intensity is detected after mixing.
CN201811066799.9A 2018-09-13 2018-09-13 A kind of kit of auxiliary detection sub-health population cancer base antigen Withdrawn CN109239332A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811066799.9A CN109239332A (en) 2018-09-13 2018-09-13 A kind of kit of auxiliary detection sub-health population cancer base antigen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811066799.9A CN109239332A (en) 2018-09-13 2018-09-13 A kind of kit of auxiliary detection sub-health population cancer base antigen

Publications (1)

Publication Number Publication Date
CN109239332A true CN109239332A (en) 2019-01-18

Family

ID=65058026

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811066799.9A Withdrawn CN109239332A (en) 2018-09-13 2018-09-13 A kind of kit of auxiliary detection sub-health population cancer base antigen

Country Status (1)

Country Link
CN (1) CN109239332A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110426520A (en) * 2019-06-18 2019-11-08 上海彧成生物科技有限公司 A kind of magnetic particle storing liquid and its preparation
CN113358868A (en) * 2021-05-24 2021-09-07 迪瑞医疗科技股份有限公司 Sperm acrosome enzyme chemiluminescence immunoassay kit and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110426520A (en) * 2019-06-18 2019-11-08 上海彧成生物科技有限公司 A kind of magnetic particle storing liquid and its preparation
CN113358868A (en) * 2021-05-24 2021-09-07 迪瑞医疗科技股份有限公司 Sperm acrosome enzyme chemiluminescence immunoassay kit and preparation method thereof

Similar Documents

Publication Publication Date Title
US10472400B2 (en) Cardiac troponin I ultra-sensitive detection reagent kit, and ultra-sensitive detection method therefor
CN107543932A (en) The magnetic microparticle chemiluminescence detection kit and preparation method of a kind of calcitonin
CN110333352A (en) Tumour related auto-antibodies and tumor markers combined detection kit
US20190317087A1 (en) Novel assay
CN108351358A (en) Liver cancer test method
CN110221084A (en) A kind of nanometer selenium kit of quick detection HE4 and CA125
CN110873711B (en) Serum TK1 detection kit based on full-automatic chemiluminescence analyzer
CN109187971A (en) Neuronspecific enolase chemiluminescence immune detection reagent kit and preparation method thereof
CN110579593A (en) kit for detecting concentration of stimulated thyroid stimulating hormone receptor antibody
CN101566633A (en) Method for diagnosing, evaluating or testing cancer and foreseeing cancer severity
CN106950374A (en) Application of the albumen of Glypican 1 in diagnosis of pancreatic cancer, the detection method of positive excretion bulk concentration and application thereof
CN109507426A (en) Prostate cancer diagnosis, classification or prognostic marker, detection reagent or kit, system and its application
CN109270269A (en) A kind of fluorescence immune chromatography detection card, kit for the multi-joint detection of early-stage breast cancer
CN113433318A (en) Kit for detecting alpha-fetoprotein heteroplasmon AFP-L3 content and detection method and application thereof
CN109239332A (en) A kind of kit of auxiliary detection sub-health population cancer base antigen
CN103439511A (en) Liquid chip kit for detection of lung cancer
CN106645756A (en) Kit for detecting NMP22 (Nuclear Matrix Protein 22) and preparation method thereof
CN103954761B (en) For oophoroma early metaphase quick diagnosis reagent kit and detection method thereof
CN101373188A (en) Tumor-associated antigen 19-9 chemical luminescence immune analytic determination reagent kit and preparation method thereof
CN107677826A (en) For sarcoma of uterus early metaphase quick diagnosis chemical luminescence reagent kit
CN104360062B (en) Application of the Peptidylarginine deiminase 1 in clinical tumor diagnostic reagent is prepared
CN109580951A (en) The kit and its application method of multispecific antibody joint-detection early liver cancer marker
CN108738347B (en) Method, device, computer program product and kit for assisting recurrence risk prediction of hepatocellular carcinoma patients
CN107918013A (en) The method and kit of K Ras albumen in chemiluminescence Enzyme immunoassay circulating tumor cell
Tazawa et al. Significance of serum lipoprotein-X and gammaglutamyltranspeptidase in the diagnosis of biliary atresia. A preliminary study in 27 cholestatic young infants

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20190118